Increasing evidence that knockdown or exogenous overexpression of SF3B1 mutations regulates tumorigenesis and progression of MDS suggests that SF3B1 represents a potential therapeutic target, and there is an urgent need for appropriate therapeutic strategies. The gene discussed is SF3B1; the disease is myelodysplastic syndrome.